July 31 Product: Johnson & Johnsons Darzalex Faspro Indication : Multiple myeloma Johnson & Johnson picked up another indication for its Darzalex Faspro Wednesday as the FDA approved the therapy, in combination with bortezomib, lenalidomide and dexamethasone, to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant
Often discussed in the context of metabolism, its gaining traction in functional medicine for its role in weight management and metabolic support, akin to well-known peptides like semaglutide and tirzepatide.[4][5] Unlike these GLP-1 agonists, which primarily mimic hormones to regulate appetite, 5-Amino-1MQ targets enzymatic pathways directly, offering a complementary mechanism that doesn't rely on hormonal simulation
International Journal of Molecular Sciences , 2018
These cells and proteins support wound repair and tissue renewal to strengthen the skin
Many researchers run these peptides together on the same protocol day for potentially enhanced GH release: CJC-1295 DAC at 12 mg/week (12 injections) and Ipamorelin at 200300 mcg/day (1 daily injection)
